7-Hydroxymitragynine (7-OH) is a minor alkaloid found naturally in kratom leaves at less than 2% of total alkaloid content. It is also produced as a metabolite when the body processes mitragynine (kratom's primary alkaloid). In concentrated extract form, 7-OH is one of the most potent opioid receptor agonists currently sold legally in the US — studies estimate it is 13× more potent than morphine at mu-opioid receptors. This makes 7-OH extracts fundamentally different from natural kratom powder in both effect intensity and risk profile. Understanding this distinction is critical before using any kratom-adjacent product.

How is 7-OH different from regular kratom?

Natural kratom leaf contains 7-OH at trace levels (under 2%), with mitragynine comprising ~66% of alkaloids and acting primarily as a partial agonist at opioid receptors. Isolated and concentrated 7-OH extracts amplify the opioid-like effect dramatically. A 2016 study in Drug and Alcohol Dependence found 7-OH binds to mu-opioid receptors with significantly higher affinity than mitragynine and with full (not partial) agonist activity. This means concentrated 7-OH extracts act more like a traditional opioid than kratom powder, with proportionally higher risk of dependence, respiratory depression at high doses, and withdrawal.

What are the effects of 7-OH?

At low doses, 7-OH produces analgesia (pain relief), sedation, and euphoria. The onset is fast — particularly with liquid extracts — often within 10–20 minutes. The effects are more intensely opioid-like than standard kratom: deeper sedation, stronger pain relief, and more pronounced mood elevation. At high doses, 7-OH can cause nausea, vomiting, severe sedation, and respiratory depression — the same risk profile as prescription opioids. Unlike kratom powder, there is very little stimulant phase with concentrated 7-OH; the effect is almost entirely sedative-analgesic from the start.

Is 7-OH legal?

As of 2026, isolated 7-OH is in a contested legal space. The DEA has proposed scheduling 7-hydroxymitragynine as a Schedule I controlled substance, citing its high opioid receptor potency. This rulemaking process has been contested by kratom advocacy groups. In its natural trace concentration within kratom leaf, 7-OH remains legal where kratom is legal. Concentrated 7-OH isolate products exist in a gray market. Some states that have specifically regulated kratom have also addressed 7-OH. The American Kratom Association now actively advocates for 7-OH-free labeling standards to distinguish natural kratom from concentrated extracts.

What are the risks of using 7-OH?

The risks of concentrated 7-OH are substantially higher than natural kratom powder. Key concerns: high dependence potential due to full mu-opioid agonism, accelerated tolerance development, withdrawal syndrome that mirrors opioid withdrawal (muscle aches, chills, insomnia, anxiety), and potential for respiratory depression at high doses. There is limited long-term human safety data specific to concentrated 7-OH products. The FDA has included 7-OH in its kratom safety concerns. People with opioid use history, respiratory conditions, or who take other CNS depressants (benzodiazepines, alcohol) should avoid 7-OH products entirely.

What does "7-OH free" mean on product labels?

A growing number of kratom brands — including Rave Kratom, carried at elevatedhaze.com — now label their products as “7-OH free.” This means the product has been processed to remove or exclude concentrated 7-hydroxymitragynine while retaining the other natural kratom alkaloids. The result is a product that still provides the energy, mood, and mild analgesic benefits associated with mitragynine but without the intense opioid-like potency and higher dependence risk of 7-OH. For new users or those who want kratom's lighter benefits without opioid-level intensity, 7-OH-free products are the recommended starting point.